Evidence map›Paper›PMID 40950685›Full record

ArticleTranslational cancer research2025

Risk factors and treatment strategies for female reproductive system carcinosarcoma with metastasis.

Huijie Wu, Peiqiong Huo, Miao Dong, Ying Xiao, Lewei Tu

Abstract read
In one paragraph

Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Huijie Wu *School of Nursing, Zhejiang Chinese Medical University, Hangzhou, China.
Peiqiong Huo *Faculty of Medicine, Macau University of Science and Technology, Macau, China.
Miao Dong *Faculty of Medicine, Macau University of Science and Technology, Macau, China.
Ying XiaoFaculty of Medicine, Macau University of Science and Technology, Macau, China.
Lewei TuSchool of Nursing, Zhejiang Chinese Medical University, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Carcinosarcomas are rare, aggressive tumors of the female reproductive tract, with limited knowledge regarding their progression, metastasis, risk factors, and treatment, especially in advanced stages. This study aimed to investigate the risk factors and treatment outcomes for metastatic carcinosarcoma using a population-based approach. Methods: A retrospective study based on the Surveillance, Epidemiology, and End Results (SEER) database was conducted in order to identify patients diagnosed with carcinosarcoma and to analyze metastatic trends and patterns. Chi-square tests, Cox regression models, and the Kaplan-Meier method were used to identify risk factors and to assess the outcomes of various treatment strategies. Results: A total of 6,479 patients with carcinosarcoma were identified, with an estimated median cancer-specific survival (CSS) of 29 months. There were 775 patients in the metastatic cohort, with an estimated median CSS of 9 months. The metastasis patterns were mostly one-site metastasis (N=318, 41.03%), and the most common metastases were lung metastasis (N=153, 19.74%), followed by liver metastasis (N=96, 12.39%). A range of variables such as age, race, marital status, stage, grade, and size were found to be risk factors for metastatic carcinosarcoma in the univariable Cox model, but only tumor size was found to be an independent risk factor in the multivariable Cox model. Surgery and chemotherapy were associated with significant increases in survival, but radiotherapy was not. Conclusions: Carcinosarcoma is rare but aggressive and often results in lung and liver metastases. We conclude from our analysis that tumor size is an independent prognostic risk factor in patients with metastases, and we recommend both surgery and chemotherapy for these patients.

Indexed as

Carcinosarcomafemale reproductive systemmetastasisSurveillance, Epidemiology, and End Results (SEER)

Identifiers

PMID40950685
PMCPMC12432793

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.